Abstract 2485
Background
Uterine sarcoma (US) is a highly malignant cancer with poor prognosis and high mortality. This study focused on identification of RNA-Seqexpressionsignature for prognosis prediction of Uterine Sarcoma.
Methods
We obtained RNA-Seqexpression profiles from The Cancer Genome Atlas (TCGA) database and differential expressed genes (DEGs) were identified between US tissues and normal tissues. Univariate Cox proportional hazards regression analysis was performed to identify Prognosis associated DEGscorrelated with survival of US patients.The RNA-Seqbased prognostic signature was identified by least absolute shrinkage and selection operator (LASSO) Cox model. The cohort was randomly divided into training and testing groups. Thebiological pathway and processof putative RNA targets was also analyzed by bioinformatics.
Results
This study identified a RNA-Seq signature based on 11 genes, AP000320.1, HNRNPA1P33, RPL21P10, AC067773.1, AC011933.3, STX19, AC091133.4, HIST1H3A, AC004988.1, AL356585.1 and HNRNPA3P1. In the training group, the median OS in the high-risk and low-risk groups were 13.7 vs 88.1 months (HR, 0.204, 95% CI, 0.08589 - 0.4846; P < 0.0001), respectively. In the testing group, the median OS in the high-risk and low-risk groups were 11.9 vs 67.2 months (HR, 0.04315, 95% CI, 0.004845 - 0.3842; P < 0.0001) respectively. Genes in the model were put into gene ontology biological process enrichment and Kyoto Encyclopedia of Genes and Genomes signaling pathways analysis, which suggested that these genes might contribute to cancer-associated processes such as the nuclear nucleosome and DNA packaging complex.
Conclusions
This 11-genebased prognostic signature may improve prognosis prediction of US.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Linguistic correction
Resources from the same session
2670 - Molecular subtypes of metastatic(met) gastric cancer(GC) (MoTriGastric): new biomarkers closer to the clinics
Presenter: Maria Alsina Maqueda
Session: Poster Display session 2
Resources:
Abstract
3797 - Exploring candidate signal transduction pathways for targeted therapy in esophageal cancer
Presenter: Aafke Creemers
Session: Poster Display session 2
Resources:
Abstract
5485 - Clinical implication of CLDN18, RhoGAP, and E-cadherin in gastric signet ring cell carcinoma
Presenter: Hyunho Kim
Session: Poster Display session 2
Resources:
Abstract
1970 - Identification of a spectrum of germline mutations for hereditary diffuse gastric cancer in the Russian population by next-generation sequencing.
Presenter: IRINA EFIMOVA
Session: Poster Display session 2
Resources:
Abstract
4989 - The molecular profiling and prognostic value of Chinese gastric signet ring cell carcinoma patients
Presenter: Jia Wei
Session: Poster Display session 2
Resources:
Abstract
7145 - A phase 2 basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors
Presenter: Alison Schram
Session: Poster Display session 2
Resources:
Abstract
1406 - Simultaneous Resection of Pancreatic Cancer and Liver Oligometastases After Induction Chemotherapy in Stage IV Patients:an Open-Label Prospective Randomized Multicenter phase 3 trial(CSPAC-1)
Presenter: Miaoyan Wei
Session: Poster Display session 2
Resources:
Abstract
1530 - Multicenter randomized phase II trial of 5-Fluorouracil/leucovorin (5-FU/LV) with or without liposomal irinotecan (nal-IRI) in metastatic biliary tract cancer (BTC) as second-line therapy after progression on gemcitabine plus cisplatin (GemCis): NIFTY trial
Presenter: Changhoon Yoo
Session: Poster Display session 2
Resources:
Abstract
1563 - A randomized phase II study of Maintenance therapy with multiepitope vaccine Tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced Pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM – PRODIGE 63 GERCOR study)
Presenter: Cindy Neuzillet
Session: Poster Display session 2
Resources:
Abstract
2780 - A phase 3, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1
Presenter: Do-Youn Oh
Session: Poster Display session 2
Resources:
Abstract